Company intelligence / Profile preview
Chongqing Fujin Biomedical
Chongqing, Chongqing, Chinafagencq.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Several recombinant protein drugs (notably pegylated recombinant consensus interferon variant for hepatitis C and recombinant insulin glargine) have reached approval or late-stage development in China. Other programs are in preclinical or pending regulatory phases, with some inactive developments (e.g., in stroke).
- Therapeutic areas
- Metabolic DisordersNeurologyInfectious DiseasesHematologyEndocrinology
- Modalities
- ProteinRecombinant proteinSmall molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Lunan Pharma (pegfilgrastim biosimilar)
Beyond the preview
Go deeper on Chongqing Fujin Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chongqing Fujin Biomedical.